Payment overview · 2025
General Payments
$1,232.06
54 reported records · 14 companies
Healthcare provider profile · identity verified
Amy Su, MD PHD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · FLUSHING, NY · NPI 1255315776
Verified facts
What the public records show
CMS Open Payments records show Amy Su, MD PHD received $1,232.06 in general payments during 2025 across 54 reported records.
Gilead Sciences, Inc. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $469.69 | 38.1% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $211.16 | 17.1% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $121.10 | 9.8% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $104.21 | 8.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $72.12 | 5.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.10 | 4.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.66 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.24 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.67 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.98 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.13 | 1.7% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $20.66 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.61 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.73 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,232.06 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $208.56 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $121.10 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $104.21 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.24 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 36 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 146 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 36 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 571 | 127 |
| Losartan Potassium | Losartan Potassium | 524 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 80 |
| Simvastatin | Simvastatin | 277 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 68 |
| Alendronate Sodium | Alendronate Sodium | 221 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 55 |
| Metformin Hcl | Metformin Hcl | 196 | 45 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 151 | 52 |
| Jardiance | Empagliflozin | 146 | 36 |
| Famotidine | Famotidine | 140 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 45 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 114 | 34 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 112 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 109 | 30 |
| Nifedipine Er | Nifedipine | 98 | 20 |
| Carvedilol | Carvedilol | 93 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 15 |
| Allopurinol | Allopurinol | 89 | 17 |
| Atenolol | Atenolol | 85 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 32 |
| Omeprazole | Omeprazole | 83 | 38 |
| Mirtazapine | Mirtazapine | 82 | 34 |
| Repaglinide | Repaglinide | 82 | 14 |
| Folic Acid | Folic Acid | 71 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 14 |
| Finasteride | Finasteride | 70 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 21 |
| Trazodone Hcl | Trazodone Hcl | 69 | 22 |
| Azithromycin | Azithromycin | 68 | 53 |
| Diclofenac Epolamine | Diclofenac Epolamine | 64 | 17 |
| Ammonium Lactate | Ammonium Lactate | 63 | 26 |
| Ketoconazole | Ketoconazole | 61 | 31 |
| Metformin Hcl Er | Metformin Hcl | 61 | 17 |
| Lisinopril | Lisinopril | 60 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 55 | 13 |
| Meclizine Hcl | Meclizine Hcl | 55 | 32 |
| Januvia | Sitagliptin Phosphate | 54 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 46 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 16 |
| Donepezil Hcl | Donepezil Hcl | 47 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 47 | suppressed |
| Eliquis | Apixaban | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 13 |
| Vemlidy | Tenofovir Alafenamide | 46 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 45 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 21 |
| Montelukast Sodium | Montelukast Sodium | 43 | 11 |
| Febuxostat | Febuxostat | 40 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 39 | 19 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 32 | 31 |
| Felodipine Er | Felodipine | 32 | suppressed |
| Furosemide | Furosemide | 32 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 13 |
| Linzess | Linaclotide | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Gabapentin | Gabapentin | 28 | suppressed |
| Nateglinide | Nateglinide | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | 13 |
| Celecoxib | Celecoxib | 26 | 17 |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 12 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 22 | 12 |
| Loperamide | Loperamide Hcl | 22 | 14 |
| Mupirocin | Mupirocin | 22 | 20 |
| Acarbose | Acarbose | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | 16 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 18 | 11 |
| Ursodiol | Ursodiol | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | 12 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Telmisartan | Telmisartan | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,232.06 · 54 records | Gilead Sciences, Inc. | ABRYSVO, AIRSUPRA, CAPVAXIVE, COLLAGENASE SANTYL, COMIRNATY, Cologuard Collection Kit, GARDASIL 9, JARDIANCE, Kerendia, LINZESS, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, UBRELVY, XIFAXAN, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error